Fredrick Van Goor1, Haihui Yu2, Bill Burton2, Beth J Hoffman2. 1. Vertex Pharmaceuticals Incorporated, 130 Waverly St, Cambridge, MA, United States; Vertex Pharmaceuticals Incorporated, 11010 Torreyana Road, San Diego, CA 92121, United States. Electronic address: fredrick_vangoor@sd.vrtx.com. 2. Vertex Pharmaceuticals Incorporated, 11010 Torreyana Road, San Diego, CA 92121, United States.
Abstract
BACKGROUND: Ivacaftor (KALYDECO™, VX-770) is a CFTR potentiator that increased CFTR channel activity and improved lung function in patients age 6 years and older with CF who have the G551D-CFTR gating mutation. The aim of this in vitro study was to evaluate the effect of ivacaftor on mutant CFTR protein forms with defects in protein processing and/or channel function. METHODS: The effect of ivacaftor on CFTR function was tested in electrophysiological studies using a panel of Fischer rat thyroid (FRT) cells expressing 54 missense CFTR mutations that cause defects in the amount or function of CFTR at the cell surface. RESULTS: Ivacaftor potentiated multiple mutant CFTR protein forms that produce functional CFTR at the cell surface. These included mutant CFTR forms with mild defects in CFTR processing or mild defects in CFTR channel conductance. CONCLUSIONS: These in vitro data indicated that ivacaftor is a broad acting CFTR potentiator and could be used to help stratify patients with CF who have different CFTR genotypes for studies investigating the potential clinical benefit of ivacaftor.
BACKGROUND:Ivacaftor (KALYDECO™, VX-770) is a CFTR potentiator that increased CFTR channel activity and improved lung function in patients age 6 years and older with CF who have the G551D-CFTR gating mutation. The aim of this in vitro study was to evaluate the effect of ivacaftor on mutant CFTR protein forms with defects in protein processing and/or channel function. METHODS: The effect of ivacaftor on CFTR function was tested in electrophysiological studies using a panel of Fischer rat thyroid (FRT) cells expressing 54 missense CFTR mutations that cause defects in the amount or function of CFTR at the cell surface. RESULTS:Ivacaftor potentiated multiple mutant CFTR protein forms that produce functional CFTR at the cell surface. These included mutant CFTR forms with mild defects in CFTR processing or mild defects in CFTR channel conductance. CONCLUSIONS: These in vitro data indicated that ivacaftor is a broad acting CFTR potentiator and could be used to help stratify patients with CF who have different CFTR genotypes for studies investigating the potential clinical benefit of ivacaftor.
Authors: Daniel T Infield; Guiying Cui; Christopher Kuang; Nael A McCarty Journal: Am J Physiol Lung Cell Mol Physiol Date: 2015-12-18 Impact factor: 5.464
Authors: Victor Rusu; Eitan Hoch; Josep M Mercader; Danielle E Tenen; Melissa Gymrek; Christina R Hartigan; Michael DeRan; Marcin von Grotthuss; Pierre Fontanillas; Alexandra Spooner; Gaelen Guzman; Amy A Deik; Kerry A Pierce; Courtney Dennis; Clary B Clish; Steven A Carr; Bridget K Wagner; Monica Schenone; Maggie C Y Ng; Brian H Chen; Federico Centeno-Cruz; Carlos Zerrweck; Lorena Orozco; David M Altshuler; Stuart L Schreiber; Jose C Florez; Suzanne B R Jacobs; Eric S Lander Journal: Cell Date: 2017-06-29 Impact factor: 41.582
Authors: Iris A L Silva; Tereza Doušová; Sofia Ramalho; Raquel Centeio; Luka A Clarke; Violeta Railean; Hugo M Botelho; Andrea Holubová; Iveta Valášková; Jiunn-Tyng Yeh; Tzyh-Chang Hwang; Carlos M Farinha; Karl Kunzelmann; Margarida D Amaral Journal: Biochim Biophys Acta Mol Basis Dis Date: 2020-07-28 Impact factor: 5.187
Authors: Nicholas M Dalesio; Melis A Aksit; Kwangmi Ahn; Karen S Raraigh; Joseph M Collaco; Sharon McGrath-Morrow; Pamela L Zeitlin; Steven S An; Garry R Cutting Journal: Int Forum Allergy Rhinol Date: 2020-04-13 Impact factor: 3.858
Authors: Carleen M Sabusap; Wei Wang; Carmel M McNicholas; W Joon Chung; Lianwu Fu; Hui Wen; Marina Mazur; Kevin L Kirk; James F Collawn; Jeong S Hong; Eric J Sorscher Journal: JCI Insight Date: 2016-09-08
Authors: Puay-Wah Phuan; Jung-Ho Son; Joseph-Anthony Tan; Clarabella Li; Ilaria Musante; Lorna Zlock; Dennis W Nielson; Walter E Finkbeiner; Mark J Kurth; Luis J Galietta; Peter M Haggie; Alan S Verkman Journal: J Cyst Fibros Date: 2018-06-12 Impact factor: 5.482
Authors: Elizabeth Matthes; Julie Goepp; Graeme W Carlile; Yishan Luo; Kurt Dejgaard; Arnaud Billet; Renaud Robert; David Y Thomas; John W Hanrahan Journal: Br J Pharmacol Date: 2016-01-13 Impact factor: 8.739